Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA x CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

被引：0

作者：

Costa, Luciano ^{[1
]}

Bar, Noffar ^{[2
]}

Mateos, Maria-Victoria ^{[3
]}

Ribas, Paz ^{[4
]}

Hansson, Markus ^{[5
]}

Paris, Laura ^{[6
]}

Hofmeister, Craig ^{[7
]}

Rodriguez-Otero, Paula

Bermudez, Maria Aranzazu ^{[9
]}

Santoro, Armando ^{[8
,10
]}

Yee, Andrew ^{[11
]}

Creignou, Maria ^{[12
]}

Encinas, Cristina ^{[13
]}

Cerchione, Claudio ^{[14
]}

de la Rubia, Javier ^{[15
]}

Oriol, Albert ^{[16
]}

Ferstl, Barbara ^{[17
]}

Besemer, Britta ^{[18
]}

Chen, Jinjie ^{[19
]}

Boss, Isaac ^{[19
]}

Gaudy, Allison ^{[19
]}

Hsu, Kevin ^{[19
]}

Godwin, Colin ^{[19
]}

San-Miguel, Jesus ^{[20
]}

Wong, Sandy ^{[21
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] Yale Univ, Sch Med, New Haven, CT USA

[3] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[4] Hosp Univ Dr Peset Aleixandre, Valencia, Spain

[5] Skane Univ Hosp, Lund, Sweden

[6] ASST Papa Giovanni XXIII, Bergamo, Italy

[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[8] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[9] Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[10] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[11] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA

[12] Karolinska Univ Hosp, Stockholm, Sweden

[13] Hosp Gen Univ Gregorio Maranon HGUGM, IiSGM, Madrid, Spain

[14] Ist Scientif Romagnolo Studio & Cura Tumori IRST, Meldola, Italy

[15] Univ Hosp La Fe, Dept Hematol, Valencia, Spain

[16] Hosp Germans Trias i Pujol, Catalan Inst Oncol & Josep Carreras Inst, Badalona, Spain

[17] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen, Germany

[18] Univ Tubingen Hosp, Tubingen, Germany

[19] Bristol Myers Squibb, Princeton, NJ USA

[20] Inst Invest Navarra, Ctr Invest Med Aplicada, Ctr Invest Biomed Red Canc, Canc Ctr Clin Univ Navarra, Pamplona, Spain

[21] Univ Calif San Francisco, San Francisco, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-033

引用

页码：S52 / S53

页数：2

共 50 条

[21] Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Popat, Rakesh
Zweegman, Sonja
Cavet, Jim
Yong, Kwee
Lee, Lydia
Faulkner, Jim
Kotsopoulou, Ekaterini
Al-Hajj, Muhammad
Thomas, Simon
Cordoba, Shaun P.
Pule, Martin
Cerec, Virginie
Peddareddigari, Vijay G. R.
Khokhar, Nushmia Z.
Menne, Tobias F.
BLOOD, 2019, 134
[22] Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
Jiang, Hua
Dong, Baoxia
Gao, Li
Liu, Li
Ge, Jian
He, Aili
Du, Juan, Jr.
Chen, Xiequn
Zhao, Yi
Han, Yu
Chen, Yuezhang
Xu, Yuesheng
Zhang, Hua
He, Jiaping
Shi, Huan
Han, Cong
Ye, Xun
Wang, Zhenguang
Liu, Jia
Shen, Lianjun
Cao, Wei
Sersch, Martina
Fu, Weijun
BLOOD, 2020, 136
[23] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Westervelt, Peter
Roboz, Gail J.
Cortes, Jorge E.
Kantarjian, Hagop M.
Lee, Sangmin
Rettig, Michael P.
Han, Tae H.
Guenot, Jeanmarie
Feldman, Eric J.
DiPersio, John F.
BLOOD, 2018, 132
[24] First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.
Berdeja, Jesus G.
Lin, Yi
Raje, Noopur S.
Siegel, David Samuel DiCapua
Munshi, Nikhil C.
Liedtke, Michaela
Jagannath, Sundar
Maus, Marcela Valderrama
Turka, Ashley
Lam, Lyh Ping
Hege, Kristen
Morgan, Richard
Quigley, M. Travis
Kochenderfer, James
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[25] Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
Krishnan, Amrita Y.
Garfall, Alfred L.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Nahi, Hareth
San-Miguel, Jesus F.
Oriol, Albert
Rosinol, Laura
Chari, Ajai
Bhutani, Manisha
Karlin, Lionel
Benboubker, Lotfi
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Stephenson, Tara
Goldberg, Jenna D.
Banerjee, Arnob
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[26] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Westervelt, Peter
Cortes, Jorge E.
Altman, Jessica K.
Long, Meixiao
Oehler, Vivian G.
Gojo, Ivana
Guenot, Jeanmarie
Chun, Patrick
Roboz, Gail J.
BLOOD, 2019, 134
[27] Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).
Du, Juan
Jiang, Hua
Dong, Baoxia
Gao, Li
Liu, Li
Ge, Jian
He, Aili
Li, Lu
Lu, Jing
Chen, Xiequn
Sersch, Martina A.
Zhao, Yi
Shen, Lianjun
Weng, Lihong
Zhang, Hua
Liu, Jia
Fu, Weijun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[28] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
Raab, M. S.
Haenel, M.
Mohty, M.
Tomasson, M. H.
Arnulf, B.
Bahlis, N. J.
Prince, H. M.
Niesvizky, R.
Rodriguez-Otero, P.
Martinez-Lopez, J.
Koehne, G.
Jethava, Y.
Gabayan, A. E.
Stevens, D. A.
Nooka, A. K.
Raje, N.
Iida, S.
Leip, E.
Conte, U.
Czibere, A.
Viqueira, A.
Lesokhin, A. M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
[29] Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Polepally, Akshanth R.
Biesdorf, Carla
Uddin, Muhammad Erfan
Boehm, Nils
Ross, Jeremy A.
Kumar, Shaji Kunnathu
Voorhees, Peter M.
D'Souza, Anita
Weisel, Katja
Bueno, Orlando
Talati, Chetasi
Menon, Rajeev M.
BLOOD, 2023, 142
[30] Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Raje, Noopur S.
Jakubowiak, Andrzej
Gasparetto, Cristina
Cornell, Robert F.
Krupka, Heike I.
Navarro, Daniel
Forgie, Alison J.
Udata, Chandrasekhar
Basu, Cynthia
Chou, Jeffrey
Leung, Abraham
Lesokhin, Alexander M.
BLOOD, 2019, 134

← 1 2 3 4 5 →